Multiple Sclerosis, Genes, Microbes, and MedicationThe purpose of the main study is to investigate adverse drug reactions from multiple sclerosis (MS) disease modifying drugs by understanding the genetic factors that contribute to their cause. Recruiting Principal Investigator Helen TremlettBody Locations and Systems Multiple Sclerosis, Immune SystemArea VancouverAge 18 and above
A Meningococcal Vaccine (Men-ACWY) Booster StudyThe purpose of this study is to determine whether there is a difference between the 3 available MenACWY vaccines in Canada (used against meningococcal infections), and if any one is better than the others.Recruiting Principal Investigator Manish SadaranganiBody Locations and Systems Meningitis, ImmunizationsArea VancouverAge Students in Grade 9
A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1)This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL). Recruiting Principal Investigator Kevin SongBody Locations and Systems Immune System and DisordersArea VancouverAge 18 and above
Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant RecipientsThe purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients. Recruiting Principal Investigator Alissa WrightBody Locations and Systems Blood, Immune System and DisordersArea VancouverAge 16 and above
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic ArthritisThe purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies. Recruiting Principal Investigator Lori TuckerBody Locations and Systems Juvenile Rheumatoid ArthritisArea VancouverAge 0-17
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)The purpose of this study is to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health status assessments (PROs), and health care resource utilization (HCRU) in a general population of moderate-toRecruiting Principal Investigator Jennifer ReynoldsBody Locations and Systems LupusArea VancouverAge 18 and above
Determinants of late initiation and treatment interruption in a context of expansion of highly active antiretroviral therapy (HAART) in British…To identify the clinical, social and cultural determinants of late HAART initiation and to determine the impact of HIV-related care (routine access to care, physician experience, physical and social barriers to care) and use of community-based organizations on HAART uptake and retention. Closed for Recruitment Principal Investigator Robert Stephen HoggBody Locations and Systems HIVArea VancouverAge 19 and above
Employment and Arthritis: Making it Work (MIW)The investigators plan to conduct a randomized controlled trial to evaluate the effectiveness and the cost effectiveness of an on-line eLearning program (entitled Employment and Arthritis: Making it Work) designed to help people with inflammatory arthritis stay employed.Closed for Recruitment Principal Investigator Diane LacailleBody Locations and Systems Psoriatic Arthritis, Rheumatoid Arthritis, Lupus, Ankylosing SpondylitisArea RichmondAge 18-59
Arthritis Health Journal Proof of Concept Study (AHJ)The purpose of this study is to determine whether an online patient passport tool called the Arthritis Health Journal can assist people with rheumatoid arthritis in managing their disease.Closed for Recruitment Principal Investigator Diane LacailleBody Locations and Systems Rheumatoid ArthritisArea VancouverAge 18 and above
